FDA Status Tracker

Approved for cardiac protection during coronary artery bypass grafting

Not FDA-approved. No completed human trials. Phase II registered for IBD.

Not FDA-approved. Limited human pharmacokinetic studies only.

Not FDA-approved. Phase I pharmacokinetic studies only.

Used in cosmetics. No FDA-approved drug applications.

Not FDA-approved

Not FDA-approved

Not FDA-approved

Clinical trials completed for postoperative ileus (Phase II) and GH deficiency. Not FDA-approved.

A synthetic melanocortin receptor agonist FDA-approved for erythropoietic protoporphyria (EPP).

FDA has issued warnings against use. Associated with serious adverse effects.

Clinical trials completed. Not FDA-approved.

Not FDA-approved as a drug

Approved in Russia only

Previously FDA-approved (1997), discontinued by manufacturer (2008). Available compounded.

Not FDA-approved

Phase 3 trials ongoing

Approved in several European countries

A hormone produced during pregnancy, used clinically for fertility treatment and hypogonadism.

Recombinant human growth hormone, FDA-approved for multiple growth hormone deficiency conditions.

A mitochondrial-derived peptide with cytoprotective properties.

Clinical trials for infertility

A naturally occurring compound required for fatty acid transport into mitochondria. Not a peptide.

No approved therapeutic applications

Phase 3 trials ongoing in China

A splice variant of IGF-1 expressed in muscle following mechanical stress.

A peptide hormone produced in the hypothalamus, known for its role in social bonding, childbirth, and lactation.

A melanocortin receptor agonist approved for hypoactive sexual desire disorder in premenopausal women.

Phase 3 trials ongoing for obesity and T2DM

Approved in Russia only

Approved for T2DM (2017), obesity (2021), cardiovascular risk reduction (2024)

Phase 3 trials in mitochondrial diseases

Phase 3 trials ongoing for obesity and NASH

A GLP-2 analog FDA-approved for short bowel syndrome.

Recombinant human parathyroid hormone 1-34, FDA-approved for osteoporosis treatment.

A GHRH analog FDA-approved specifically for HIV-associated lipodystrophy.

Approved in 30+ countries including Italy and China. US IND for COVID-19.

A dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and obesity. First-in-class dual incretin agonist.

Clinical trials for sepsis and autoimmune diseases

Clinical trials for obesity discontinued due to lack of efficacy

Limited clinical trials with mixed results

No human clinical trials in Western countries

Clinical trials completed but not approved

A tripeptide fragment of alpha-MSH with anti-inflammatory properties.

No human clinical trials